USPTO 2015–2025 USPTO PatentsView US Corporation

AIM ImmunoTech Inc.

USPTO PatentsView assignee record - 5 granted patents across 9 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, AIM ranks #44,516 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 9 technology areas.

#44,516
of 49,997 US assignees by volume
Top 21%
by Innovation Score (46.2/100)
15.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44516 · US Corporation #44,516 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • LOWER-Q #44,516/49,997
  • PHOTO-FINISH Ai-musics Technology
  • CPC-NARROW A61P · 9 areas
  • INNOV-PAR 46.2/100
  • CLAIMS-RICH 15.6 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2023–2025 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ai-musics Technology Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around AIM

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows AIM's Innovation Score is 46.2/100 (top 21% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where AIM's grants concentrate

AIM ImmunoTech Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2024. By volume, AIM sits between Ai-musics Technology Inc. and Aion Co., Ltd..

AIM's three-year grant acceleration

AIM ImmunoTech Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at AIM's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows AIM holds 5 patents at rank #44,452, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near AIM

By rank, the assignees closest to #44,452 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in AIM's primary technology class.

AIM's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202320242025 1
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
AIM ImmunoTech Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 3 60.0%
2024 1 20.0%
2025partial year 1 20.0%

Where it ranks

Overall rank by patents

#44,516

of 49,997 tracked assignees

Innovation Score

46.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

AIM ImmunoTech Inc.'s patent record in context - here's where to go next.

  • AIM ImmunoTech Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #44,516 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare AIM ImmunoTech Inc. against Ai-musics Technology Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 46.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.